Pacific Sun Financial Corp Sells 475 Shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Pacific Sun Financial Corp reduced its stake in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 7.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 6,293 shares of the company’s stock after selling 475 shares during the quarter. Pacific Sun Financial Corp’s holdings in Invesco Biotechnology & Genome ETF were worth $419,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in PBE. Howe & Rusling Inc. bought a new position in Invesco Biotechnology & Genome ETF in the 3rd quarter worth about $31,000. Jane Street Group LLC bought a new position in shares of Invesco Biotechnology & Genome ETF during the third quarter valued at approximately $295,000. Creative Financial Designs Inc. ADV boosted its stake in shares of Invesco Biotechnology & Genome ETF by 5.6% during the third quarter. Creative Financial Designs Inc. ADV now owns 5,630 shares of the company’s stock valued at $393,000 after purchasing an additional 299 shares in the last quarter. HighTower Advisors LLC boosted its stake in shares of Invesco Biotechnology & Genome ETF by 64.1% during the third quarter. HighTower Advisors LLC now owns 7,101 shares of the company’s stock valued at $494,000 after purchasing an additional 2,774 shares in the last quarter. Finally, IHT Wealth Management LLC boosted its stake in shares of Invesco Biotechnology & Genome ETF by 14.7% during the third quarter. IHT Wealth Management LLC now owns 12,124 shares of the company’s stock valued at $847,000 after purchasing an additional 1,550 shares in the last quarter.

Invesco Biotechnology & Genome ETF Stock Performance

NYSEARCA PBE opened at $68.37 on Thursday. The firm’s 50 day moving average price is $68.18 and its 200-day moving average price is $69.10. Invesco Biotechnology & Genome ETF has a 52-week low of $59.32 and a 52-week high of $72.84. The company has a market cap of $276.21 million, a PE ratio of 17.12 and a beta of 0.88.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.